Patiromer
Based on 1 Customer Validation
Patiromer is an orally active, selective and non-absorbable intestinal potassium (K+) polymer binder that reversibly binds potassium ions in exchange for calcium (Ca2+). Patiromer can rapidly and continuously reduce serum potassium levels, maintain a normal blood potassium state, and reduce serum aldosterone levels. Patiromer also increases fecal potassium excretion. Patiromer is mainly used in the study of hyperkalemia associated with diseases such as chronic kidney disease, diabetes, and heart failure, and is particularly suitable for improving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy.
For research use only. We do not sell to patients.
- Purity: 95.0%
- CAS No.: 1208912-84-8
- Formula: C28H48CaFO2+
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
JAK3 33.1 nM (IC50) |
IL-2 |
IL-4 |
IL7R |
IL-15 |
STAT3 |
STAT5 |
STAT6 |
Patiromer is a sodium-free, non-absorbable K+ binding polymer[2].
Patiromer has a significantly higher potassium binding capacity in vitro than traditional resins such as polystyrene sulfonate and has high-capacity potassium binding properties[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Dosing Preparation:
This product is orally active and is routinely administered via gavage or feed. For gavage administration, due to its poor water solubility, prepare the dosage based on the daily powder requirement and volume for each animal before administration. The specific procedure is as follows:
Weigh the appropriate amount of powder and add an appropriate amount of drinking water. Vortex or stir thoroughly. The powder will not completely dissolve at this point; the system will be a homogeneous suspension. Administer the solution via gavage immediately after preparation. If powder residue remains in the container after administration, add a small amount of pure water, stir well, and administer via gavage again immediately. Repeat this step if necessary to ensure the animal ingests all the powder.
Precautions:
1. The gavage volume must be strictly controlled within a reasonable range. For rats and mice, it is recommended not to exceed 10 mL/kg.
2. This product is poorly soluble in water; the suspension should be used immediately after preparation and should not be stored for extended periods.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Spontaneously hypertensive rats (SHR) (male, 200-250 g, 7-9 weeks old) with unilateral nephrectomy (UniNx)[2]
-
Dosage:4 g/kg
-
Administration:Oral gavage, once daily, 8 days; rats were induced chronic hyperkalemia by 3% potassium diet and amiloride.
-
Result:Significantly reduced serum K+ from baseline at days 4 and 8, and serum aldosterone was reduced to baseline levels, with no significant clinical distress in animals.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1208912-84-8
-
Appearance Solid
-
Formula C28H48CaFO2+
-
Color White to light yellow
-
SMILES
CCC(C([O-])=O)(F)CC(C1=CC=CC=C1)CC(CCCCC(C)CC)C.CC(CC)C.[Ca+2].[p].[p].[n].[m].[n].[1/2]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
H2O : < 0.1 mg/mL (insoluble)
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Weir MR, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15;372(3):211-21. [Content Brief]
[2]. Iyer SPN, et al. Pharmacodynamic effects of the K+ binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats. Physiol Rep. 2020 Sep;8(18):e14572. [Content Brief]
[3]. Colbert GB, et al. Patiromer for the treatment of hyperkalemia. Expert Rev Clin Pharmacol. 2020 Jun;13(6):563-570. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)